Keywords: Curis, Debiopharm, Debio 0932, Bioniche, Endo, Bladder Cancer, Urocidin

Curis and Bioniche each get $8 million milestones in respective deals with Debiopharm and Endo

Article | 15 February 2010

Print This

Massachusetts, USA-based drug developer Curis is set to receive an $8 million payment from Switzerland’s Debiopharm SA after the latter ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in